A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 20 May 2018
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms BREEZE-AD2
- Sponsors Eli Lilly; Eli Lilly Japan
- 09 Mar 2018 Planned End Date changed from 15 Feb 2019 to 16 Nov 2018.
- 09 Mar 2018 Planned primary completion date changed from 18 Jan 2019 to 19 Oct 2018.
- 12 Dec 2017 Planned End Date changed from 8 Mar 2019 to 15 Feb 2019.